Back

Phase 1 trial of a monoclonal antibody targeting the angiopoietin-like protein 3/8 complex in patients with mixed hyperlipidaemia

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Nature Medicine: 2025 highlights Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Daniel Gaudet

ECOGENE-21 and Community gene medicine center, clinical lipidology unit, Montreal (Canada)

3 More presentations in this session

Presentation thumbnail
Effect of LOX-1 inhibition on coronary atherosclerosis among patients with residual inflammation after myocardial infarction
Doctor M. O'Donoghue (Boston, US)
Slides Video
Presentation thumbnail
Effects of vutrisiran on echocardiographic measures of cardiac structure and function: the HELIOS-B trial
Doctor K. Jering (Boston, US)
Slides Video
Presentation thumbnail
Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid-lowering
Doctor N. Marston (Boston, US)
Slides Video

Access the full session

Session thumbnail
Nature Medicine: 2025 highlights
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in serum triglyceride and non-HDL cholesterol concentrations: first human results with ARO-ANG3
thumbnail
Congress Presentation
Discussion
thumbnail
Congress Presentation
Ongoing research and hope for patients with elevated Lp(a)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources